Latest News and Press Releases
Want to stay updated on the latest news?
-
The shelf prospectus supplement, the corresponding base shelf prospectus and any amendment to the documents is accessible through SEDAR+, or will be accessible through SEDAR+ within 2 business days,...
-
SYDNEY, March 16, 2026 (GLOBE NEWSWIRE) -- Innovation Beverage Group Limited (NASDAQ: IBG) (the “Company”), an innovative developer, manufacturer, and marketer of a growing beverage portfolio of 60...
-
SAN DIEGO, March 16, 2026 (GLOBE NEWSWIRE) -- Judicate West, one of California’s leading providers of private dispute resolution services, has added retired San Diego County Superior Court Judge...
-
WATERTOWN, Mass, March 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with...
-
New data shows positive real-world impact of the world’s first and only one-year CGM, with a full year of strong patient adherence, glucometrics and hypoglycemic outcomes Eversense 365 delivered...
-
SYDNEY, March 13, 2026 (GLOBE NEWSWIRE) -- Innovation Beverage Group Limited (NASDAQ: IBG) (the “Company”), an innovative developer, manufacturer, and marketer of a growing beverage portfolio of 60...
-
SAN DIEGO, March 04, 2026 (GLOBE NEWSWIRE) -- Judicate West, one of California’s leading providers of private dispute resolution services, has added retired San Diego County Superior Court Judge...
-
– Both pivotal Phase 3 trials for DURAVYU in wet AMD on track for data readout beginning in mid-2026 – – Patients dosed in both COMO and CAPRI Phase 3 clinical trials for DURAVYU in DME – –...
-
– Active Phase 3 programs for DURAVYU in wet AMD and DME, the two largest multi-billion-dollar retinal disease markets – – Topline data for DURAVYU in DME anticipated in 2H 2027 – WATERTOWN, Mass.,...
-
WATERTOWN, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with...